Agenus presents new data on balstilimab and agen2373 in asco abstracts

Lexington, mass., may 20, 2021 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced data on the differentiated activity profile of balstilimab, an anti-pd-1 antibody, and new phase 1 clinical data for agen2373, a cd137 agonist antibody, as published in abstracts for two posters to be presented at the american society for clinical oncology (asco) annual meeting 2021 from june 4 – 8, 2021.
AGEN Ratings Summary
AGEN Quant Ranking